Abstract
Despite a promising response rate and good tolerability profile, phase III randomized trial data do not justify the use of pazopanib for metastatic renal cell carcinoma over existing treatment options. Evidence confirming efficacy superior to sunitinib or everolimus is required to justify its consideration in first-line or second-line therapy, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
